# US 2013/0252264 A1 · Methods and compositions for the evaluation of renal injury using hyaluronic acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252264 A1
- Document ID: US20130252264A1
- Status: Published application
- Kind: A1
- Application number: 13/825,675
- Filed: 2011-09-23
- Published: 2013-09-26
- Earliest claimed: 2010-09-24
- Assignees: Astute Medical, Inc.
- Inventors: Joseph Anderberg; Jeff Gray; Paul McPherson; Kevin Nakamura; James Patrick Kampf; Kai Singbartl; John A. Kellum
- Web page: https://patentgrep.com/patent/US20130252264A1

## CPC

- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 2400/40: Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of hyaluronic acid (HA) as diagnostic and prognostic biomarker assays in renal injuries.

## Claims

### Claim 1

A method for evaluating renal status in a subject not receiving renal replacement therapy, comprising:
performing one or more assays configured to detect one or more of HA on a body fluid sample obtained from the subject to provide one or more assay results; and
correlating the assay result(s) to one or more of risk stratification, prognosis, classifying and monitoring of the renal status of the subject.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the subject is not in acute renal failure.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the subject has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

### Claim 4 (depends on 1)

A method according to claim 1, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 12 hours preceding the time at which the body fluid sample is obtained.

### Claim 5 (depends on 1)

A method according to claim 1, wherein the subject has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

### Claim 6 (depends on 1)

A method according to claim 1, wherein the subject (i) has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 12 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

### Claim 7 (depends on 1)

A method according to claim 1, wherein the subject is in RIFLE stage 0 or R.

### Claim 8 (depends on 7)

A method according to claim 7, wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 72 hours.

### Claim 9 (depends on 7)

A method according to claim 7, wherein the subject is in RIFLE stage 0 or R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours.

### Claim 10 (depends on 9)

A method according to claim 9, wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.

### Claim 11 (depends on 9)

A method according to claim 9, wherein the subject is in RIFLE stage R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours.

### Claim 12 (depends on 1)

A method according to claim 1, wherein the subject is in RIFLE stage 0, R, or I, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.

### Claim 13 (depends on 12)

A method according to claim 12, wherein the subject is in RIFLE stage I, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.

### Claim 14 (depends on 8)

A method according to claim 8, wherein said correlating step comprises assigning likelihood that the subject will reach RIFLE stage R, I or F within 48 hours.

### Claim 15 (depends on 9)

A method according to claim 9, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours.

### Claim 16 (depends on 10)

A method according to claim 10, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours.

### Claim 17 (depends on 11)

A method according to claim 11, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.

### Claim 18 (depends on 12)

A method according to claim 12, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.

### Claim 19 (depends on 13)

A method according to claim 13, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.

### Claim 20 (depends on 14)

A method according to claim 14, wherein said correlating step comprises assigning likelihood that the subject will reach RIFLE stage R, I or F within 24 hours.

### Claim 21 (depends on 15)

A method according to claim 15, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours.

### Claim 22 (depends on 16)

A method according to claim 16, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours.

### Claim 23 (depends on 17)

A method according to claim 17, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.

### Claim 24 (depends on 18)

A method according to claim 18, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.

### Claim 25 (depends on 19)

A method according to claim 19, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.

### Claim 26 (depends on 1)

A method according to claim 1, wherein said assay result(s) comprise a measured urine concentration of HA and said correlation step comprises comparing said measure concentration to a threshold concentration, and
assigning an increased likelihood of progressing to a worsening RIFLE stage to the subject, relative to the subject's current RIFLE stage, when the measured concentration is above the threshold, or assigning a decreased likelihood of progressing to a worsening RIFLE stage to the subject, relative to the subject's current RIFLE stage, when the measured concentration is below the threshold.

### Claim 27 (depends on 1)

A method according to claim 1, wherein said assay result(s) comprise a measured urine concentration of HA and said correlation step comprises comparing said measure concentration to a threshold concentration, and
assigning an increased likelihood of progressing to a need for renal replacement therapy to the subject when the measured concentration is above the threshold, or assigning a decreased likelihood of progressing to a need for renal replacement therapy when the measured concentration is below the threshold.

### Claim 28 (depends on 1)

A method according to claim 1, wherein said assay result(s) comprise a measured urine concentration of HA and said correlation step comprises comparing said measure concentration to a threshold concentration, and
assigning an increased likelihood of progressing to a worsening RIFLE stage to the subject, relative to the subject's current RIFLE stage, when the measured concentration is above the threshold, or assigning a decreased likelihood of progressing to a worsening RIFLE stage to the subject, relative to the subject's current RIFLE stage, when the measured concentration is below the threshold.

### Claim 29 (depends on 2)

A method according to claim 2, wherein said assay result(s) comprise a measured urine concentration of HA and said correlation step comprises comparing said measure concentration to a threshold concentration, and
assigning an increased likelihood of progressing to acute renal failure when the measured concentration is above the threshold, or assigning a decreased likelihood of progressing to acute renal failure to the subject when the measured concentration is below the threshold.

### Claim 30 (depends on 8)

A method according to claim 8, wherein said assay result(s) comprise a measured urine concentration of HA and said correlation step comprises comparing said measure concentration to a threshold concentration, and
assigning an increased likelihood of progressing to RIFLE stage R, I or F to the subject, when the measured concentration is above the threshold, or assigning a decreased likelihood of progressing to RIFLE stage R, I or F to the subject when the measured concentration is below the threshold.

### Claim 31 (depends on 9)

A method according to claim 9, wherein said assay result(s) comprise a measured urine concentration of HA and said correlation step comprises comparing said measure concentration to a threshold concentration, and
assigning an increased likelihood of progressing to RIFLE stage I or F to the subject, when the measured concentration is above the threshold, or assigning a decreased likelihood of progressing to RIFLE stage I or F to the subject when the measured concentration is below the threshold.

### Claim 32 (depends on 10)

A method according to claim 10, wherein said assay result(s) comprise a measured urine concentration of HA and said correlation step comprises comparing said measure concentration to a threshold concentration, and
assigning an increased likelihood of progressing to RIFLE stage F to the subject, when the measured concentration is above the threshold, or assigning a decreased likelihood of progressing to RIFLE stage F to the subject when the measured concentration is below the threshold.

### Claim 33 (depends on 11)

A method according to claim 11, wherein said assay result(s) comprise a measured urine concentration of HA and said correlation step comprises comparing said measure concentration to a threshold concentration, and
assigning an increased likelihood of progressing to RIFLE stage F to the subject, when the measured concentration is above the threshold, or assigning a decreased likelihood of progressing to RIFLE stage I or F to the subject when the measured concentration is below the threshold.

### Claim 34 (depends on 12)

A method according to claim 12, wherein said assay result(s) comprise a measured urine concentration of HA and said correlation step comprises comparing said measure concentration to a threshold concentration, and
assigning an increased likelihood of progressing to RIFLE stage F to the subject, when the measured concentration is above the threshold, or assigning a decreased likelihood of progressing to RIFLE stage F to the subject when the measured concentration is below the threshold.

### Claim 35 (depends on 13)

A method according to claim 13, wherein said assay result(s) comprise a measured urine concentration of HA and said correlation step comprises comparing said measure concentration to a threshold concentration, and
assigning an increased likelihood of progressing to RIFLE stage F to the subject, when the measured concentration is above the threshold, or assigning a decreased likelihood of progressing to RIFLE stage F to the subject when the measured concentration is below the threshold.

### Claim 36 (depends on 1)

A method according to claim 1, wherein the subject is selected for evaluation of renal status based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF.

### Claim 37 (depends on 1)

A method according to claim 1, wherein the subject is selected for evaluation of renal status based on an existing diagnosis of one or more of congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, sepsis, injury to renal function, reduced renal function, or ARF, or based on undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery, or based on exposure to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin.

### Claim 38

Urine measurement of HA for the risk stratification, prognosis, classifying and monitoring of renal status of a subject not receiving renal replacement therapy.

### Claim 39

Urine measurement of HA for the risk stratification, prognosis, classifying and monitoring of renal status of a subject not in acute renal failure.

### Claim 40

Urine measurement of HA for assigning an increased likelihood of progressing to a worsening RIFLE stage to a subject, relative to the subject's current RIFLE stage.
